...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pain Studies and Treatment >Prolonged Opioid-Sparing Pain Control after Hemorrhoidectomy with Liposome Bupivacaine: Results from a Cohort of 95 Patients
【24h】

Prolonged Opioid-Sparing Pain Control after Hemorrhoidectomy with Liposome Bupivacaine: Results from a Cohort of 95 Patients

机译：脂质体布比卡因痔切除术后延长的类阿片疼痛控制：来自95名患者的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of this retrospective study was to examine the effects of an intraoperative injection of liposome bupivacaine on the quality and duration of postsurgical pain control, patient satisfaction, and opioid use in a cohort of patients undergoing hemorrhoidectomy in an outpatient setting. Patients underwent ambulatory hemorrhoidectomy conducted by a single surgeon. Liposome bupivacaine 266 mg/20 mL was administered via infiltration at the end of surgery. After discharge, pain-related outcomes were assessed via telephone interviews. Outcomes of interest included first onset of pain after surgery, patient-reported pain intensity (0 = no pain; 10 = worst pain imaginable), time to first use of orally administered opioids after surgery, number of opioid tablets consumed postsurgery, and patient’s satisfaction with postsurgical pain control. A total of 95 patients were included; the average number of hemorrhoids excised was 3.0 (median, 2.7) per patient. Mean time to first onset of pain after surgery was 36 hours; mean time to first consumption of postsurgical opioids was 38 hours. Mean pain intensity scores remained <5 through 72 hours after surgery. The average number of opioid analgesic tablets consumed after surgery was 12.4; 13% (12/95) of patients required no postsurgical opioids. Seventy-five percent of patients reported being “very satisfied” or “perfectly satisfied” with their overall pain control. No liposome bupivacaine-related adverse events were observed. A single intraoperative injection of liposome bupivacaine safely facilitated ambulatory hemorrhoidectomy, eliminated the need for intravenous opioids, minimized opioid use, and was associated with high levels of patient satisfaction.
机译：这项回顾性研究的目的是在门诊患者中，对接受痔疮切除术的一组患者进行术中注射布比卡因脂质体对术后疼痛控制的质量和持续时间，患者满意度以及使用阿片类药物的影响。患者由一名外科医生进行非卧床痔切除术。在手术结束时通过浸润施用266 mg / 20 mL脂质体布比卡因。出院后，通过电话采访评估与疼痛有关的结局。感兴趣的结果包括手术后首次出现疼痛，患者报告的疼痛强度（0 =无疼痛; 10 =可想象的最严重疼痛），术后首次口服阿片类药物的时间，术后服用的阿片类药物片的数量以及患者的满意度术后疼痛控制。共有95例患者被纳入研究。每位患者平均切除的痔疮数量为3.0（中位数为2.7）。手术后首次出现疼痛的平均时间为36小时。术后首次服用阿片类药物的平均时间为38小时。术后72小时，平均疼痛强度评分保持<5。术后平均消耗的阿片类镇痛片数量为12.4; 13％（12/95）的患者不需要术后阿片类药物。百分之七十五的患者报告对他们的总体疼痛控制“非常满意”或“完全满意”。没有观察到与布比卡因脂质体相关的不良事件。术中单次注射布比卡因脂质体可安全地促进非卧床痔切除术，消除了对静脉内阿片类药物的需要，减少了阿片类药物的使用，并提高了患者的满意度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号